Isaac Francos-Quijorna

Isaac Francos-Quijorna

Auto-generated profile, based on publicly available information

Isaac Francos-Quijorna

Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), Consejo Superior de Investigaciones Científicas (CSIC)–Universidad Autónoma de Madrid (UAM), Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2016 in Glia
Verified
Journal Article
Open access
PDF file
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
JAJesús Amo-Aparicio
Jesús Amo-Aparicio
AMAnna Martinez-Muriana
Anna Martinez-Muriana
RLRuben Lopez-Vales
Ruben Lopez-Vales
Macrophages and microglia play a key role in the maintenance of nervous system homeostasis. However, upon different challenges, they can adopt several phenotypes, which may lead to divergent effects on tissue repair. After spinal cord injury (SCI), microglia and macrophages show predominantly pro-inflammatory activation and contribute to tissue damage. However, the factors that hamper their conversion to an anti-inflammatory state after SCI, or to other protective phenotypes, are poorly understood. Here, we show that IL-4 protein levels are undetectable in the spinal cord after contusion injury, which likely favors microglia and macrophages to remain in a pro-inflammatory state. We also demonstrate that a single delayed intraspinal injection of IL-4, 48 hours after SCI, induces increased expression of M2 marker in microglia and macrophages. We also show that delayed injection of IL-4 leads to the appearance of resolution-phase macrophages, and that IL-4 enhances resolution of inflammation after SCI. Interestingly, we provide clear evidence that delayed administration of IL-4 markedly improves functional outcomes and reduces tissue damage after contusion injury. It is possible that these improvements are mediated by the presence of macrophages with M2 markers and resolution-phase macrophages. These data suggest that therapies aimed at increasing IL-4 levels could be valuable for the treatment of acute SCI, for which there are currently no effective treatments. GLIA 2016;64:2079–2092

13 May 2016 in Scientific Reports
Verified
Journal Article
Open access
AMAnna Martínez-Muriana
Anna Martínez-Muriana
RMRenzo Mancuso
Renzo Mancuso
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
AOAdrian Olmos-Alonso
Adrian Olmos-Alonso
RORosario Osta
Rosario Osta
RLRuben Lopez-Vales
Ruben Lopez-Vales
Inflammation is a common neuropathological feature in several neurological disorders, including amyotrophic lateral sclerosis (ALS). We have studied the contribution of CSF1R signalling to inflammation in ALS, as a pathway previously reported to control the expansion and activation of microglial cells. We found that microglial cell proliferation in the spinal cord of SOD1G93A transgenic mice correlates with the expression of CSF1R and its ligand CSF1. Administration of GW2580, a selective CSF1R inhibitor, reduced microglial cell proliferation in SOD1G93A mice, indicating the importance of CSF1-CSF1R signalling in microgliosis in ALS. Moreover, GW2580 treatment slowed disease progression, attenuated motoneuron cell death and extended survival of SOD1G93A mice. Electrophysiological assessment revealed that GW2580 treatment protected skeletal muscle from denervation prior to its effects on microglial cells. We found that macrophages invaded the peripheral nerve of ALS mice before CSF1R-induced microgliosis occurred. Interestingly, treatment with GW2580 attenuated the influx of macrophages into the nerve, which was partly caused by the monocytopenia induced by CSF1R inhibition. Overall, our findings provide evidence that CSF1R signalling regulates inflammation in the central and peripheral nervous system in ALS, supporting therapeutic targeting of CSF1R in this disease.

6 November 2017 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
ESEva Santos-Nogueira
Eva Santos-Nogueira
KGKarsten Gronert
Karsten Gronert
ASAaron B. Sullivan
Aaron B. Sullivan
MKMarcel A. Kopp
Marcel A. Kopp
RLRuben Lopez-Vales
Ruben Lopez-Vales
Resolution of inflammation is defective after spinal cord injury (SCI), which impairs tissue integrity and remodeling and leads to functional deficits. Effective pharmacological treatments for SCI are not currently available. Maresin 1 (MaR1) is a highly conserved specialized proresolving mediator (SPM) hosting potent anti-inflammatory and proresolving properties with potent tissue regenerative actions. Here, we provide evidence that the inappropriate biosynthesis of SPM in the lesioned spinal cord hampers the resolution of inflammation and leads to deleterious consequences on neurological outcome in adult female mice. We report that, after spinal cord contusion injury in adult female mice, the biosynthesis of SPM is not induced in the lesion site up to 2 weeks after injury. Exogenous administration of MaR1, a highly conserved SPM, propagated inflammatory resolution after SCI, as revealed by accelerated clearance of neutrophils and a reduction in macrophage accumulation at the lesion site. In the search of mechanisms underlying the proresolving actions of MaR1 in SCI, we found that this SPM facilitated several hallmarks of resolution of inflammation, including reduction of proinflammatory cytokines (CXCL1, CXCL2, CCL3, CCL4, IL6, and CSF3), silencing of major inflammatory intracellular signaling cascades (STAT1, STAT3, STAT5, p38, and ERK1/2), redirection of macrophage activation toward a prorepair phenotype, and increase of the phagocytic engulfment of neutrophils by macrophages. Interestingly, MaR1 administration improved locomotor recovery significantly and mitigated secondary injury progression in a clinical relevant model of SCI. These findings suggest that proresolution, immunoresolvent therapies constitute a novel approach to improving neurological recovery after acute SCI.SIGNIFICANCE STATEMENTInflammation is a protective response to injury or infection. To result in tissue homeostasis, inflammation has to resolve over time. Incomplete or delayed resolution leads to detrimental effects, including propagated tissue damage and impaired wound healing, as occurs after spinal cord injury (SCI). We report that inflammation after SCI is dysregulated in part due to inappropriate synthesis of proresolving lipid mediators. We demonstrate that the administration of the resolution agonist referred to as maresin 1 (MaR1) after SCI actively propagates resolution processes at the lesion site and improves neurological outcome. MaR1 is identified as an interventional candidate to attenuate dysregulated lesional inflammation and to restore functional recovery after SCI.

1 February 2021 in Cancer Cell
Verified
Journal Article
Closed access
SASultan Abdul-Jawad
Sultan Abdul-Jawad
LBLuca Baù
Luca Baù
TAThanussuyah Alaguthurai
Thanussuyah Alaguthurai
IBIrene del Molino del Barrio
Irene del Molino del Barrio
ALAdam G. Laing
Adam G. Laing
SISheeba Irshad
Sheeba Irshad

19 January 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MCMarina Coll-Miró
Marina Coll-Miró
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
ESEva Santos-Nogueira
Eva Santos-Nogueira
ATAbel Torres-Espín
Abel Torres-Espín
PBPhilip Buffler
Philip Buffler
RLRuben Lopez-Vales
Ruben Lopez-Vales
Significance: Spinal cord injury (SCI) often results in severely impaired locomotor, sensory, and autonomic function. Although inflammation contributes to the physiopathology of SCI, several clinical trials of high doses of dexamethasone or methylprednisolone have not resulted in improved recovery of function. IL-37, a member of the IL-1 family, exerts broad antiinflammatory effects in several mouse models of inflammatory diseases. We report here that mice expressing human IL-37 exhibit reduced inflammation in the central nervous system and demonstrate significantly improved functional disabilities following SCI. The administration of recombinant forms of human IL-37 enhances motor skills after SCI, suggesting that IL-37 could provide a new therapeutic approach to limit the harmful effects of inflammation in neurologic conditions.

17 October 2012 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
AKArmelle Klopstein
Armelle Klopstein
ESEva Santos-Nogueira
Eva Santos-Nogueira
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
ARAdriana Redensek
Adriana Redensek
SDSamuel David
Samuel David
RLRuben Lopez-Vales
Ruben Lopez-Vales
αB-crystallin is a member of the heat shock protein family that exerts cell protection under several stress-related conditions. Recent studies have revealed that αB-crystallin plays a beneficial role in a mouse model of multiple sclerosis, brain ischemia, and Alexander disease. Whether αB-crystallin plays a role in modulating the secondary damage after CNS trauma is not known. We report here that αB-crystallin mediates protective effects after spinal cord injury. The levels of αB-crystallin are reduced in spinal cord tissue following contusion lesion. In addition, administration of recombinant human αB-crystallin for the first week after contusion injury leads to sustained improvement in locomotor skills and amelioration of secondary tissue damage. We also provide evidence that recombinant human αB-crystallin modulates the inflammatory response in the injured spinal cord, leading to increased infiltration of granulocytes and reduced recruitment of inflammatory macrophages. Furthermore, the delivery of recombinant human αB-crystallin promotes greater locomotor recovery even when the treatment is initiated 6 h after spinal cord injury. Our findings suggest that administration of recombinant human αB-crystallin may be a good therapeutic approach for treating acute spinal cord injury, for which there is currently no effective treatment.